US 11,998,591 B2
Method of treating diabetes type 2 by administering ultrarapid acting insulin
Peter Richardson, Ringoes, NJ (US); Robert A. Baughman, Brookfield, CT (US); Elizabeth Potocka, Cambridge, MA (US); Anders Hasager Boss, Princeton, NJ (US); and Richard Petrucci, Tampa, FL (US)
Assigned to MannKind Corporation, Danbury, CT (US)
Filed by MannKind Corporation, Westlake Village, CA (US)
Filed on Nov. 25, 2020, as Appl. No. 17/105,399.
Application 15/910,876 is a division of application No. 14/102,383, filed on Dec. 10, 2013, granted, now 9,943,571, issued on Apr. 17, 2018.
Application 13/351,855 is a division of application No. 12/539,459, filed on Aug. 11, 2009, granted, now 8,119,593, issued on Feb. 21, 2012.
Application 17/105,399 is a continuation of application No. 15/910,876, filed on Mar. 2, 2018, granted, now 10,857,207.
Application 14/102,383 is a continuation of application No. 13/351,855, filed on Jan. 17, 2012, granted, now 8,623,817, issued on Jan. 7, 2014.
Claims priority of provisional application 61/138,863, filed on Dec. 18, 2008.
Claims priority of provisional application 61/097,516, filed on Sep. 16, 2008.
Claims priority of provisional application 61/097,495, filed on Sep. 16, 2008.
Claims priority of provisional application 61/087,943, filed on Aug. 11, 2008.
Prior Publication US 2021/0138040 A1, May 13, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/28 (2006.01); A61K 9/00 (2006.01); A61K 47/54 (2017.01)
CPC A61K 38/28 (2013.01) [A61K 9/0021 (2013.01); A61K 9/0075 (2013.01); A61K 47/545 (2017.08)] 11 Claims
 
1. A method of treating diabetes type 2 in a subject with well or moderately controlled fasting blood glucose (FBG) but poorly controlled post-prandial glucose (PPG), and in need of avoiding weight gain, comprising:
selecting said patient with diabetes type 2 currently being treated with metformin but not a basal insulin who is in need of improved glycemic control and who would be a candidate for combination treatment with said metformin and an insulin secretagogue, said patient having an HbA1c level less than or equal to 8.4%; and
instead combining treatment with said metformin with routinely administering an ultrarapid acting insulin (URAI) preparation with at least one established meal, wherein said treatment results in reduced weight gain as compared to metformin treatment alone.